(VIANEWS) – FibroGen (NASDAQ: FGEN) shares have experienced an abysmal 27.61% drop over 21 sessions from EUR1.34 on August 11th to EUR0.97 as of 10:40 EST Tuesday morning, following two consecutive gains for the NASDAQ which currently is up 0.12% at EUR13,900.96. FibroGen closed at EUR0.95, a remarkable 96.31% lower than its 52-week high price of EUR25.69
About FibroGen
FibroGen is a biopharmaceutical company founded in 1993 that specializes in discovering, developing, and marketing therapeutics to address unmet medical needs. Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor in Phase III clinical development for idiopathic pulmonary fibrosis, pancreatic cancer and Duchenne muscular dystrophy; Roxadustat is an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity which has successfully completed Phase III trials for anemia related to chronic kidney disease across multiple countries and also undergone phase III development for myelodysplastic syndromes; collaboration agreements exist with Astellas Pharma Inc and AstraZeneca AB. FibroGen is headquartered out of San Francisco California
Yearly Analysis
Based on available data, FibroGen’s stock is currently trading at EUR0.97; which is significantly lower than its 52-week high of EUR25.69 but higher than its 52-week low of EUR0.90 – suggesting it may have experienced some degree of volatility over the past year.
FibroGen anticipates sales growth of 10.5% for this year and 8.6% in 2019, which provides an indicator of its growth potential. Unfortunately, their estimated growth rate could slow in subsequent years.
FibroGen currently stands with an EBITDA ratio of -0.54, suggesting negative profits prior to taking into account interests, taxes, depreciation and amortization expenses. This may cause concern among investors as negative EBITDA indicates difficulty with turning profits.
Overall, investors should carefully assess FibroGen’s financial performance and growth prospects before making investment decisions. Before investing, conducting further research on its fundamentals and industry outlook may also be prudent.
Technical Analysis
FibroGen stock has recently experienced an alarming decline, falling significantly below both its 50-day and 200-day moving averages. Furthermore, last reported volume was only 509,401 which indicates a lack of investor trust for FibroGen’s performance.
FibroGen’s intraday variation averages have demonstrated an upward trend during the past week, month, and quarter in terms of volatility, with 8.32% average weekly volatility seen across these timeframes versus 6.06% monthly and 4.72% quarterly averages respectively.
FibroGen’s stock currently falls within the realm of oversoldness as indicated by a reading of less than 20, suggesting it may be undervalued and due for an upturn soon.
Overall, FibroGen’s current stock price seems to be the result of multiple factors, including low investor confidence and overall market conditions deterioration. However, given that FibroGen stock is considered oversold and volatile trading patterns indicate positive potential rebound opportunities may exist in the near future.
Quarter Analysis
FibroGen has experienced sales growth of 134.7% compared to last year during this quarter; we expect this momentum to continue over the coming quarters with an estimated increase of 14.6%.
Revenue growth over the last twelve months for the company stands at 48.7%, which indicates an impressive performance in terms of revenue growth. This momentum should continue in this quarter with estimated growth estimated at 36.7% and into next quarter with expected growth estimated at 45.7%.
Overall, FibroGen has demonstrated strong sales and revenue growth, which could be an encouraging sign for investors. It should be remembered that past performance doesn’t guarantee future results and prior to making investment decisions they should also carefully consider other aspects such as its financial health and competitive landscape.
Equity Analysis
FibroGen currently generates an EPS of EUR-3.23 over its past twelve month period, signalling to potential investors that the company is failing to generate profits for their shareholders and may cause them some cause for alarm.
Return on Equity (ROE) for the last 12 months stands at negative -1015.79%, suggesting that shareholder equity is not producing any returns, which should serve as a warning signal to potential investors.
FibroGen investors should proceed with caution when considering investing in FibroGen, as its current financial performance does not indicate a profitable venture. Before making any decisions about investing, prospective investors must carefully assess additional financial data like revenue and cash flow as well as business strategy before making their final investment decision.
More news about FibroGen (FGEN).
